July 21: Navigating to the Safe Harbor: What to Know in Advance

The last decade has been a time of tremendous growth in the biotechnology and biopharmaceutical industries, not only in the United States, but globally. At the same time, advances in drug development technologies and accelerated approval pathways in the USFDA and in other regulatory bodies have dramatically shortened the timeline and reduced the clinical risk profile in going from concept to commercial product. During this time of accelerated global research and development regarding diagnostics and treatments–especially for COVID-19 (SARS-CoV2)–it is more important than ever for pharma/biotech companies to determine in advance whether their programs are headed for rocky seas or the safe harbor.
Join Fish attorneys Teresa Lavoie and Brian Coggio on Tuesday, July 21, for a webinar covering these issues and more, including:

• The basics of § 271(e)(1) safe harbor
• “Basic research” and the Coronavirus
• Developments regarding
• Stockpiling
• Research tools
• Companion diagnostics
• Genetically-engineered animals.

Title:
Navigating to the Safe Harbor: What to Know in Advance
Webinar Date+Time:
Tuesday, July 21, 2020
1:30 pm EDT
Register Now!
Speakers:
Fish attorneys Teresa Lavoie and Brian Coggio
By:
Fish & Richardson, P.C.
Credit:
Fish & Richardson is an accredited CLE provider by the California, New York, and Texas State Continuing Legal Education Boards. (California Provider Number 4933). Fish & Richardson will apply for 1.0 hour of CLE credit in some additional states. Credit will be awarded only to attorneys who report their required CLE states during their registration process and who log in and complete the webinar in its entirety. Note that Fish is unable to grant CLE credit to attendees who listen to the audio portion only.
Register Now!